Neurogene (NGNE) Competitors $21.47 -0.79 (-3.55%) Closing price 04:00 PM EasternExtended Trading$21.47 0.00 (0.00%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. PAHC, ABCL, NTLA, AMPH, WVE, AUPH, ARDX, ELVN, VERV, and NAGEShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors Phibro Animal Health AbCellera Biologics Intellia Therapeutics Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals Ardelyx Enliven Therapeutics Verve Therapeutics Niagen Bioscience Neurogene (NASDAQ:NGNE) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Is NGNE or PAHC more profitable? Phibro Animal Health has a net margin of 2.68% compared to Neurogene's net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -36.16% -32.51% Phibro Animal Health 2.68%30.51%6.89% Does the media favor NGNE or PAHC? In the previous week, Phibro Animal Health had 5 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Phibro Animal Health and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Phibro Animal Health's score of 0.76 indicating that Neurogene is being referred to more favorably in the media. Company Overall Sentiment Neurogene Very Positive Phibro Animal Health Positive Do analysts recommend NGNE or PAHC? Neurogene presently has a consensus target price of $46.17, indicating a potential upside of 115.03%. Phibro Animal Health has a consensus target price of $24.40, indicating a potential downside of 20.16%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Phibro Animal Health 2 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.83 Which has better earnings and valuation, NGNE or PAHC? Phibro Animal Health has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$930K329.21-$75.14M-$4.35-4.94Phibro Animal Health$1.02B1.22$2.42M$0.7839.18 Which has more volatility & risk, NGNE or PAHC? Neurogene has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Do insiders and institutionals have more ownership in NGNE or PAHC? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 9.9% of Neurogene shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryPhibro Animal Health beats Neurogene on 10 of the 16 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$317.47M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-4.9420.2228.5719.58Price / Sales329.21293.85424.2194.37Price / CashN/A43.1536.0257.93Price / Book1.037.568.135.54Net Income-$75.14M-$55.11M$3.24B$257.73M7 Day Performance5.87%7.56%2.03%0.95%1 Month Performance8.65%11.47%8.29%10.68%1 Year Performance-53.28%0.88%28.40%15.67% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene3.422 of 5 stars$21.47-3.5%$46.17+115.0%-47.7%$317.47M$930K-4.9490Positive NewsPAHCPhibro Animal Health3.9886 of 5 stars$29.90+6.8%$24.40-18.4%+80.4%$1.13B$1.02B38.331,940Gap UpHigh Trading VolumeABCLAbCellera Biologics2.2703 of 5 stars$4.03+6.1%$7.50+86.1%+35.9%$1.13B$28.83M-7.20500News CoverageAnalyst ForecastHigh Trading VolumeNTLAIntellia Therapeutics4.3048 of 5 stars$10.25-4.6%$33.37+225.5%-53.7%$1.11B$57.88M-1.96600AMPHAmphastar Pharmaceuticals4.2845 of 5 stars$22.86-1.5%$32.33+41.4%-43.3%$1.09B$731.97M8.282,028News CoverageWVEWAVE Life Sciences4.4065 of 5 stars$7.06+1.6%$20.50+190.4%+39.5%$1.08B$108.30M-8.40240AUPHAurinia Pharmaceuticals3.012 of 5 stars$7.47-1.6%$11.50+53.9%+61.1%$1.03B$235.13M26.68300Positive NewsARDXArdelyx4.0659 of 5 stars$4.35+1.9%$10.89+150.3%-21.7%$1.02B$333.61M-19.7790ELVNEnliven Therapeutics2.7808 of 5 stars$19.59-5.5%$41.20+110.3%-7.0%$1.02BN/A-10.2050VERVVerve Therapeutics3.0155 of 5 stars$11.16-1.1%$14.57+30.6%+63.9%$1.01B$59.61M-5.29110NAGENiagen Bioscience0.7441 of 5 stars$12.44-2.1%$19.50+56.8%N/A$1.00B$99.60M73.18120News Coverage Related Companies and Tools Related Companies PAHC Alternatives ABCL Alternatives NTLA Alternatives AMPH Alternatives WVE Alternatives AUPH Alternatives ARDX Alternatives ELVN Alternatives VERV Alternatives NAGE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGNE Stock Alerts